Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma

Advances in Dermatology

Volumn 20, Issue , 2004, Pages 217-235

  Berger, Carole L ^a   Mariwalla, Kavita ^a   Girardi, Michael ^a   Edelson, Richard L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; METHOXSALEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTATION; APOPTOSIS; CANCER GROWTH; CELL ACTIVATION; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE PRODUCTION; DENDRITIC CELL; EXTRACORPOREAL PHOTOPHERESIS; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOTHERAPY; LEUKAPHERESIS; PHENOTYPE; PROTEIN EXPRESSION; PUVA; REVIEW; SAFETY; T CELL LYMPHOMA; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; CUTANEOUS T CELL LYMPHOMA; HUMAN; PHYSIOLOGY; SKIN TUMOR;

DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 16544365656     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (64)

1. Edelson RL, Berger CL, Raafat J, et al: Karyotype studies of cutaneous T cell lymphoma: Evidence for clonal origin. J Invest Dermatol 73:548-550, 1979.
2. Edelson R: Cutaneous T cell lymphoma (mycosis fungoides, Sezary syndrome and other variants). J Am Acad Dermatol 2:89-106, 1980.
3. Picker LJ, Michie SA, Rott LS, et al: A unique phenotype of skin-associated lymphocytes in humans: Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 136:1053-1068, 1990.
4. Broder S, Edelson R, Lutzner M, et al: The Sézary syndrome: A malignant proliferation of helper T cells. J Clin Invest 58:1297-1306, 1997.
5. Berger C, Warburton D, Raafat J, et al: Cutaneous T cell lymphoma: Neoplasm of T cells with helper activity. Blood 53:642-651, 1979.
6. Berger CL, Longley BJ, Imaeda S, et al: Tumor-specific peptides in cutaneous T-cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 76:304-311, 1998.
7. Rowden G, Phillips TM, Lewis MG, et al: Target role of Langerhans cells in mycosis fungoides: Transmission and immuno-electron microscopic studies. J Cutan Pathol 6:364-382, 1979.
8. Banchereau J, Briere F, Caux C, et al: Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811, 2000.
9. Tan RS, Butterworth CM, McLaughlin H, et al: Mycosis fungoides: A disease of antigen persistence. Br J Dermatol 91:607-616, 1974.
10. Berger CL, Hanlon D, Kanada D, et al: The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 99:2929-2938, 2002.
11. Lutzner M, Edelson R, Schein P, et al: Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides and related disorders. Ann Intern Med 83:534-552, 1975.
12. Burg G, Rodt H, Grosse-Wilde H, et al: Surface markers and mitogen response of cells harvested from cutaneous infiltrates in mycosis fungoides and Sézary's syndrome. J Invest Dermatol 70:257-259, 1978.
13. Dalloul A, Laroche L, Bagot M, et al: Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest 90:1054-1060, 1992.
14. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: The near future. Int J Cancer 4:459-473, 2001.
15. Lutz MB, Schuler G: Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity? Trends Immunol 23:445-449, 2002.
16. + T cells with regulatory properties by repetitive stimulation with allogeneic immature dendritic cells. J Exp Med 92:1213-1222, 2000.
17. Sakaguchi SN, Sakaguchi J, Shimizu S, et al: Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18-32, 2001.
18. Sakaguchi S, Wood KJ: Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3:199-210, 2003.
19. Steinman RM, Hawiger D, Kang L, et al: Dendritic cell function in vivo during the steady state: A role in peripheral tolerance. Ann N Y Acad Sci 987:15-25, 2003.
20. Horwitz DA, Zheng SG, Gray JD, et al: The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol 74:471-478, 2003.
21. Egen JG, Kuhns MS, Allison JP: CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618, 2002.
22. Ueda H, Howson JMM, Esposito L, et al: Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 30:1-6, 2003.
23. Dieckmann D, Plottner H, Berchtold S, et al: Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med 193:1303-1310, 2001.
24. Levings MK, Bacchetta R, Schutz U, et al: The role of IL-10 and TGF-beta in the differentiation and effector function of T-regulatory cells. Int Arch Allergy Immunol 129:263-276, 2002.
25. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 198:1875-1886, 2003.
26. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421:388-392, 2003.
27. Jonuleit H, Schmitt F, Kakirman H, et al: Infectious tolerance: Human CD25+ regulatory T cells convey suppressor activity to conventional CD4+ T helper cells. J Exp Med 196:255-260, 2002.
28. Prud'homme GJ, Piccirillo CA: The inhibitory effects of transforming growth factor-beta-1 (TGF-β1) in autoimmune diseases. J Autoimmun 14:23-42, 2000.
29. + progenitors. J Leukoc Biol 66:781-791, 1999.
30. Geissman F, Prost C, Monnet J-P, et al: Transforming growth factor β1 in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med 187:961-966, 1998.
31. Chambers CA, Kuhns M, Egen JG, et al: CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-594, 2001.
32. 319 phosphorylation: A potential role for tyrosine phosphatases. J Immunol 168:4420-4429, 2002.
33. Brocker T: Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J Exp Med 186:1223-1232, 1997.
34. + T cell help. J Exp Med 186:65-70, 1997.
35. Berger C, Wang N, Christensen I, et al: The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 107:392-397, 1996.
36. Winter D, Fiebiger E, Meraner P, et al: Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma. J Immunol 171:2714-2724, 2003.
37. Edelson R, Berger CL, Gasparro FP, et al: Treatment of leukemic cutaneous T-cell lymphoma with extracorporeally-photoactivated 8-methoxypsoralen. N Engl J Med 316:297-303, 1987.
38. Edelson R, Fackto M, Andrews A, et al: Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis. N Engl J Med 291:293-294, 1974.
39. Zic JA, Stricklin GP, Greer JP, et al: Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 35:935-945, 1996.
40. Jiang SB, Dietz SB, Kim M, et al: Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: A 9.7 year experience. Photodermatol Photoimmunol Photomed 15:161-165, 1999.
41. Wollina U, Liebold K, Katz M, et al: Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. Oncol Rep 7:1197-1201, 2000.
42. Crovetti G, Carabelli A, Berti E, et al: Photopheresis in cutaneous T-cell lymphoma: Five-year experience. Int J Artif Organs 23:55-62, 2000.
43. Girardi M, Schechner J, Glusac E, et al: Transimmunization and the evolution of extracorporeal photochemotherapy. Transfus Apher Sci 3:181-190, 2002.
44. Berger CL, Xu AL, Hanlon D, et al: Induction of human tumor-loaded dendritic cells. Int J Cancer 4:438-447, 2001.
45. Yoo EK, Rook AH, Elenitsas R, et al: Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: Relevance in mechanism of therapeutic action. J Invest Dermatol 107:235-242, 1996.
46. Berger CL, Hanlon D, Kanada D, et al: Transimmunization, a novel approach for tumor immunotherapy. Transfus Apher Sci 26:205-216, 2002.
47. Jonuleit H, Kuhn U, Muller G, et al: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135-3142, 1997.
48. Maraskovsky E, Daro E, Roux E, et al: In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96:878-884, 2000.
49. Santini SM, Belardelli F: Advances in the use of dendritic cells and new adjuvants for the development of therpeutic vaccines. Stem Cells 21:495-505, 2003.
50. Antony PA, Restifo NP: Commentary: Do CD4+CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25:202-206, 2002.
51. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218, 2002.
52. Woo EY, Yeh H, Chu CS, et al: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276, 1999.
53. Rook AH, Wood GS, Yoo EK, et al: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion egression and cytotoxic T-cell responses. Blood 94:902-908, 1999.
54. Akira S, Takeda K, Kaisho T: Toll-like receptors critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680, 2001.
55. Wysocka M, Zahi MH, French LE, et al: Sézary syndrome patients demonstrate a defect in dendritic cell populations: Effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 100:3287-3294, 2002.
56. Gilchrest BA, Parrish J, Tanenbaum L, et al: Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 38:683-689, 1976.
57. Quirós PA, Jones GW, Kacinski BM, et al: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38:1027-1035, 1997.
58. Olsen EA, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of DAB389IL-2 (ONTAK) for the treatment of cutaneous T cell lymphoma. J Clin Oncol 19:376-388, 2001.
59. Najafian N, Sayegh MH: CTLA4-Ig: A novel immunosuppressive agent. Expert Opin Investig Drugs 9:2147-2157, 2000.
60. Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al: Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790-1800, 2000.
61. Maier T, Tun-Kyi A, Tassia A, et al: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102:2338-2344, 2003.
62. Knobler RM, Graninger W, Lindmaier A, et al: Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus: A pilot study. Arthritis Rheum 35:319-323, 1992.
63. Rook AH, Jegasothy BV, Heald P, et al: Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 112:303-305, 1990.
64. Barr ML, Meiser B, Eisen HJ, et al: Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 339:1744-1751, 1998.